Top Markets
Coin of the day
OncoSec Medical Incorporated OncoSec Medical Incorporated

OncoSec Medical Incorporated

ONCS
주식 순위 #40489
OncoSec Medical Incorporated is a late-stage immuno-oncology firm dedicated to... OncoSec Medical Incorporated is a late-stage immuno-oncology firm dedicated to creating, advancing, and bringing to market DNA-based therapeutics designed for direct injection into tumors. These therapies aim to activate and amplify the body's anti-cancer immune responses. Its primary therapeutic candidate, ImmunoPulse IL-12 (also known as TAVO), employs an electroporation device to administer DNA encoding interleukin-12 directly into tumors, thereby counteracting the tumor's immunosuppressive environment. OncoSec's clinical pipeline includes several programs for ImmunoPulse IL-12. In combination with KEYTRUDA, it is being investigated for advanced melanoma (under a collaboration and supply agreement, KEYNOTE-695) and for metastatic triple-negative breast cancer (currently in Phase II trials, KEYNOTE-890). Earlier Phase II trials of ImmunoPulse IL-12 combined with KEYTRUDA for advanced or metastatic melanoma, and ImmunoPulse IL-12 as a monotherapy for metastatic melanoma, have both been completed. The company has also completed a Phase II monotherapy biomarker study for advanced or metastatic TNBC. Furthermore, OncoSec is developing its technology for broader application in treating various visceral lesions, including those in the liver, lungs, bladder, and pancreas. Strategic alliances are central to OncoSec's strategy, including clinical trial collaborations with Merck & Co., Inc. for the KEYNOTE-695 and KEYNOTE-890 studies. Research collaborations include Duke University's Center for Applied Therapeutics, exploring TAVO alongside a HER2-plasmid vaccine, and Roswell Park Comprehensive Cancer Center, focusing on intravital microscopy and enhanced IL-12 DNA-plasmids. The company also collaborates with Providence Cancer Institute. Originally incorporated in 2008 as NetVentory Solutions Inc., the company rebranded to OncoSec Medical Incorporated in March 2011 and operates from its headquarters in Pennington, New Jersey.
주가
$0.2772
마지막 동기화: 2023-06-23
시가총액
$134.97K
변동 (1일)
31.87%
변동 (1년)
0.00%
국가
US
거래 OncoSec Medical Incorporated (ONCS)

카테고리

B의 시가 총액을 가진 ONCS의 가격
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
$0.2772
의 시가총액 OncoSec Medical Incorporated(ONCS)
시가총액: $134.97K
August 2026 기준으로 OncoSec Medical Incorporated의 시가총액은 $134.97K입니다. 이는 당사 데이터에 따르면 OncoSec Medical Incorporated이 세계에서 40489th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2011부터 2026까지 OncoSec Medical Incorporated의 시가총액 기록
ONCS 가장 인기있는 상위 5 가지 stocks과 비교하여
ONCS의 가격 자산 b b의 시장 결과
OncoSec Medical Incorporated OncoSec Medical Incorporated
$11,233,183 $134.97K
$5.470T +4,052,374,628.24%
OncoSec Medical Incorporated OncoSec Medical Incorporated
$9,176,940 $134.97K
$4.468T +3,310,584,166.50%
OncoSec Medical Incorporated OncoSec Medical Incorporated
$8,569,499 $134.97K
$4.173T +3,091,449,601.93%
OncoSec Medical Incorporated OncoSec Medical Incorporated
$7,599,115 $134.97K
$3.700T +2,741,383,247.21%
OncoSec Medical Incorporated OncoSec Medical Incorporated
$5,862,169 $134.97K
$2.854T +2,114,779,373.27%